Senators in New Mexico have passed a bill that will allow pharmacists in the state to substitute biosimilar products in place of the original or reference product, similar to what they currently are allowed to do with generic drugs.
The Albuquerque Journal reports that the state Senate voted 39-0 in favor of Senate Bill 180, which promises to give flexibility and control costs for some of the most expensive, and effective, biological products being used to treat a plethora of conditions—from cancer to rheumatoid arthritis to irritable bowel syndrome. The next step is approval of House Bill 260, now with the House Business and industry Committee in New Mexico.
The argument rests on drug costs. Between 2014 and 2016, the state-run Medicaid program saw a huge increase in the biological drug spend, which they associated with a 5% increase in state-funded plan members who were using adalimumab (Humira) and etanercept (Enbrel). The 2-year period saw a 52% increase in plan costs for those 2 drugs. Overall, state-run plans spent $13.3 million on anti-inflammatory agents in the year 2015—a 20% increase from 2014.
With budget impact in focus, lawmakers in New Mexico will debate whether pharmacists can substitute these expensive antibodies for cheaper “replicates,” and whether this substitution can lower consumer cost. This would require the blessings of the prescribing physician, who has the authority to write “no substitution” on the prescription.
The biosimilar approval process has been slow in the United States, with numerous legal and regulatory barriers preventing product application and launch. To date, just 1 biosimilar to adalimumab has been approved—Amgen’s Amjevita—but patent lawsuits will push product launch to 2018. Another product, manufactured by Sandoz, has delayed its abbreviated Biologics Licensed Application or aBLA.
Sandoz has also developed a biosimilar to etanercept (etanercept-szzs, Erelzi), but faces patent claims by Amgen, the developer of the original product.
Biosimilar competition will hopefully subdue the skyrocketing price of these biologicals. Abbvie, the manufacturer of Humira, has steadily raised the price of this antibody by over 70% in just a few years ($49,000 annually before discounts and $27,665 after discounts), likely due to broadening indications of the drug. Amgen has followed a similar route with Enbrel, which costs $4000 for a 30-day supply.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.